DMF: a promising therapeutic option in CTCL

Abstract

In this issue of Blood, Nicolay et al present their exciting findings that show that dimethyl fumarate (DMF) specifically inhibits NF-κB activity in cutaneous T-cell lymphoma (CTCL) cells, thus inducing their apoptosis, while having minimal effect on healthy T cells (see figure). Their study suggests that DMF may represent a new promising therapeutic option in CTCL.